Boehringer Ingelheim completed the acquisition of Saiba Animal Health.

Boehringer Ingelheim, a biopharmaceutical company, completed the acquisition of Saiba Animal Health, a provider of veterinary vaccines. Financial terms were not disclosed. “Our pets live longer which creates different needs for their medical care, and often without good existing treatment options. As a research-driven company, we are very excited about the potential of Saiba Animal Health’s groundbreaking technology platform, which could result in a more specific and longer-lasting therapeutic response to chronic diseases in companion animals than current approaches”, Eric Haaksma, Boehringer Ingelheim Head of Global Innovation.